2 Biotech Firms Join IPO Fray With Plans To Raise $211M
Two drug developers, metabolism-focused Fractyl Health Inc. and psychiatry-focused Alto NeuroScience Inc., joined a growing pipeline of initial public offerings Monday by unveiling plans for IPOs that could net $211 million...To view the full article, register now.
Already a subscriber? Click here to view full article